NCT06043700Active, not recruiting
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
A Community-Based Screening Program to Identify, Using Blood-Based Biomarkers, Individuals With or Without Alzheimer's Disease Symptoms Who Are at High Risk for Brain Amyloid Pathology
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
The primary purpose of this study is to identify participants with or without symptoms of Alzheimer's Disease (AD) that are at high risk for brain amyloid pathology using blood-based biomarkers.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 12 Sept 2023
- Start date
- 12 Sept 2023
- Primary completion date
- 31 Mar 2028
- Lead sponsor
- Eisai Limited
- Diseases
- Alzheimer disease
- NCT number
- NCT06043700
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 12 Sept 2023 to the primary completion date, 31 Mar 2028
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known uncontrolled medical conditions (example, cardiac, respiratory, gastrointestinal, psychiatric, renal disease, malignant neoplasm)
Other
- Participation in an interventional clinical trial study at the time of consent
Who the study is looking for
- Male or female, age 50 to 80 years inclusive, at the time of informed consent
- \- Those 50 to 64 years of age must have 1 of the following risk factors confirmed prior to blood sample collection:
- First degree relative with dementia onset before age 75,
- Known before screening to have at least 1 Apolipoprotein E4 (APOE4) allele, or
- Known before screening to have elevated brain amyloid according to previous positron emission tomography (PET), cerebrospinal fluid (CSF), or blood testing
- Provide written informed consent
- Willing and able to comply with all aspects of the protocol
- Willing to be referred to a clinical site if the assessment results meet the criteria
Age in the registry: 50 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Clermont | United States | Unknown status |
| - Coordinator of this site? Confirm its status | District Heights | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Lady Lake | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.